Inavolisib (Itovebi) for Locally Advanced or Metastatic Breast Cancer
转移性乳腺癌
医学
乳腺癌
肿瘤科
内科学
癌症
标识
DOI:10.58347/tml.2024.1715f
摘要
Inavolisib (Itovebi – Genentech), an oral kinase inhibitor, has been approved by the FDA for use in combination with palbociclib and fulvestrant for treatment of endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer. This is the first approval for Itovebi; palbociclib and fulvestrant have been available for years for treatment of HR-positive, HER2-negative breast cancer.